#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives

**Peter Attia** (0:11)
Hey, everyone, welcome to the Drive podcast. I'm your host, Peter Attia. This podcast, my website and my weekly newsletter all focus on the goal of translating the science of longevity into something accessible for everyone. Our goal is to provide the best content in health and wellness, and we've established a great team of analysts to make this happen. It is extremely important to me to provide all of this content without relying on paid ads. To do this, our work is made entirely possible by our members, and in return, we offer exclusive member-only content and benefits above and beyond what is available for free. If you want to take your knowledge of this space to the next level, it's our goal to ensure members get back much more than the price of the subscription. If you want to learn more about the benefits of our premium membership, head over to peterattiamd.com/subscribe.
Welcome to a special episode of The Drive. In this episode, I'm going to walk through a single topic in-depth, and this is prostate cancer screening, something that I'm very passionate about. And because we consider this a really important PSA, no pun intended, the full episode and the detailed show notes for this discussion will be available to everyone regardless of whether or not you're a premium subscriber.
In this episode, I discuss why advanced and metastatic prostate cancer diagnoses are rising despite the availability of screening tools, what PSA actually measures, and why it's more useful when interpreted over time than it is in a single one-off number, how MRI, PSA density, PSA velocity, and improved biopsy techniques can reduce unnecessary procedures while improving the detection of aggressive cancers, how active surveillance helps avoid overtreatment in men with low-risk cancers, why the evidence used to argue against PSA screening was deeply flawed, how drugs like finasteride, which are commonly used to prevent hair loss, can suppress PSA and lead to missed warning signs if clinicians and patients are not vigilant, and why I think regular PSA testing is so important if one of our objectives in life would be to eliminate prostate cancer mortality. So without further delay, I hope you enjoy this special episode of The Drive.
Well, today I want to dig into something that I feel quite strongly about and something that I think we're getting wrong at the population level in a way that is measurably costing lives. We're going to talk about prostate cancer screening, specifically PSA testing, and why I believe the current guidelines have failed men, and obviously what I think a more modern approach to screening should look like in 2026 and beyond. And this is really a discussion that I think is relevant for anybody listening to this as a potential patient, someone who cares about a patient or whether you're a clinician.
I'm going to spend some time towards the end of this discussion on something that I also think is dangerously underappreciated, which is the interaction between a drug called finasteride. This is a drug that literally millions of men are taking for hair loss prevention and how that drug interacts with our ability to interpret PSA correctly. Because if you're on finasteride and your doctor doesn't understand the implications of that and how that impacts your PSA values, you could be sitting on a ticking time bomb without anybody knowing it. Let me set the stage. Prostate cancer is the second leading cause of cancer death in men, with only lung cancer claiming more lives. About one in eight men will receive a prostate cancer diagnosis at some point in their lives, and this year alone, roughly 36,000 American men will die from it.
So what makes this disease both uniquely hopeful and uniquely frustrating, is that when you catch it early, the prognosis is outstanding. So we're talking about a 15-year survival rate approaching 97 percent from first diagnosis, and we have detection tools that are simple, widely available, and getting more sophisticated every year. And yet here we are watching the rates of advanced stage prostate cancer climb. That's right. So the rates at which advanced prostate cancer is showing up is higher today than it was 15 years ago. Recent data out of both the United States and Canada confirm what many urologists have been warning about for years. We're catching more and more of these cancers only after they have already metastasized or spread. And that's what we call stage four disease. And once you're at stage four, the picture changes dramatically. Five-year survival falls to 38 percent, and the median time from diagnosis to death is about two and a half years. So the question that I think demands an answer is quite straightforward. How did we get here? We have the screening tools, we have effective therapies for early cancers. Why are outcomes getting worse instead of better? And of course, most critically, then what do we need to do about this? Now, to answer any of that, you need to start with the basics of what the PSA actually is because it's the linchpin of this entire conversation. And quite frankly, if we had the PSA equivalent for every other cancer, the world could look a heck of a lot different than it does today with respect to cancer mortality. So PSA, which stands for prostate-specific antigen, has been available as a blood test since the early 90s. It's a protein made by the prostate gland. Its biological function is to help keep seminal fluid in a liquid state.